Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.
Saved in:
| Title: | Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review. |
|---|---|
| Authors: | Valerio, Maria Rosaria1 (AUTHOR), Sambataro, Daniela2,3 (AUTHOR), Martorana, Federica3,4,5 (AUTHOR), Greco, Martina1,4 (AUTHOR), Mesi, Chiara1,5 (AUTHOR), Gebbia, Vittorio3,6 (AUTHOR) vittorio.gebbia@unikore.it, Vigneri, Paolo4,5,7 (AUTHOR), Scandurra, Giuseppa3,7 (AUTHOR) |
| Source: | Current Oncology. Apr2026, Vol. 33 Issue 4, p198. 20p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
